Fulvestrant
Not Tagged
['breast']
results from the phase 3 sonia trial were just presented at #asco23. researchers found that cdk4/6 inhibitors are just as effective when used as a second line therapy vs. first line therapy for metastatic #breastcancer, which is the current standard of care.
A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally.
https://t.co/dvoS7vv1mZ